Incyte Corp (INCY) officer Pablo J. Cagnoni, President, Global Head of R&D, exercised employee stock options on October 15, 2026, for four lots: 839 shares at $71.93, 423 at $61.76, 455 at $61.18 and 925 at $64.25 per share. He also reported selling 2,642 common shares at $112.71 per share. The reported transactions were made pursuant to a Rule 10b5-1 plan.
Incyte Corp. officer Pablo Cagnoni filed a notice of a proposed sale of 2,642 common shares, with an aggregate market value of $297,779.82 and an approximate sale date of October 15, 2026, on Nasdaq. The notice identifies the shares as acquired from the issuer through a stock option exercise for cash on October 15, 2026. It also lists five prior sales dated July 31 through September 15, 2026.
Incyte Corp EVP, Head of Incyte Intl Lee Heeson had 463 shares of common stock withheld by the issuer on October 1, 2026, at a reported price of $117.14 per share, to satisfy tax withholding obligations due at settlement of previously reported restricted stock units.
Lee Heeson’s reported post-transaction position was 37,578 shares, including an aggregate of 26,884 shares issuable pursuant to previously reported RSUs that had not vested.
Incyte Corporation director Julian C. Baker acquired 322 shares of Common Stock on September 30, 2026, under the Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees of $40,500; the shares were fully vested. A footnote says the two indirect acquisition entries represent a single grant of 322 RSUs reported for 667, L.P. and Baker Brothers Life Sciences LP, each with an indirect proportionate pecuniary interest. Baker Bros. Advisors LP held voting and dispositive power over the shares.
Incyte Corp (INCY) director Paul J. Clancy acquired 203 restricted shares on September 30, 2026, under the company’s Amended and Restated 2010 Stock Incentive Plan, in lieu of quarterly director retainer fees. The shares were fully vested, with a reported price of $121.35 per share. Clancy’s reported direct holdings after the award were 25,838 shares, including 1,642 shares issuable under previously reported unvested restricted stock units. The election was intended to comply with Rule 10b5-1.
Incyte Corp. director Edmund Harrigan acquired 206 fully vested restricted shares on September 30, 2026. They were issued under the company’s Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees, following an election intended to comply with Rule 10b5-1. The reported per-share amount was $121.35.
Harrigan reported 23,225 shares following the transaction; that amount includes 1,642 shares issuable under previously reported restricted stock units that have not vested.
Incyte Corp reported that its EVP, Chief Strategy Officer, David H. Gardner, had 920 common shares automatically withheld on September 22, 2026, to satisfy tax withholding obligations at settlement of previously reported restricted stock units; the reported price was $126.93 per share. His reported direct position after the transaction was 15,904 shares, including 14,467 shares issuable under previously reported restricted stock units that had not vested. No Rule 10b5-1 plan is reported.
INCYTE CORP executive Pablo J. Cagnoni, President and Global Head of R&D, reported option exercises and share sales on September 15, 2026. He exercised employee stock options for 23,218 shares of common stock at exercise prices between $61.18 and $71.93 per share and sold 23,218 shares at about $120.50 per share. The company indicates these transactions were made under a Rule 10b5-1 trading plan.
INCYTE CORP (INCY) reports that officer Pablo Cagnoni has filed a notice under Rule 144 to potentially sell up to 23,218 shares of Incyte common stock, expected on September 15, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ, following recent sales reported over the prior three months.
INCYTE CORP (INCY) announced an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) aimed at improving patient access to its medicines while supporting continued U.S. biopharmaceutical innovation. Under this agreement, state Medicaid programs will be able to access Incyte’s products Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations.
Incyte also expects that, under this arrangement, it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. The company stated that it does not expect this agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook.